Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MDxHealth (MDXH) Cash & Equivalents (2020 - 2025)

MDxHealth (MDXH) has disclosed Cash & Equivalents for 6 consecutive years, with $29.0 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 38.03% to $29.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $29.0 million through Dec 2025, down 38.03% year-over-year, with the annual reading at $29.0 million for FY2025, 38.03% down from the prior year.
  • Cash & Equivalents hit $29.0 million in Q4 2025 for MDxHealth, down from $46.8 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $58.5 million in Q4 2021 to a low of $15.5 million in Q4 2022.
  • Historically, Cash & Equivalents has averaged $34.4 million across 5 years, with a median of $29.0 million in 2025.
  • Biggest five-year swings in Cash & Equivalents: surged 266.69% in 2021 and later plummeted 73.5% in 2022.
  • Year by year, Cash & Equivalents stood at $58.5 million in 2021, then tumbled by 73.5% to $15.5 million in 2022, then soared by 44.36% to $22.4 million in 2023, then soared by 109.11% to $46.8 million in 2024, then crashed by 38.03% to $29.0 million in 2025.
  • Business Quant data shows Cash & Equivalents for MDXH at $29.0 million in Q4 2025, $46.8 million in Q4 2024, and $22.4 million in Q4 2023.